Prostate Cancer clinical trials
Showing 351–400 of 735 active trials. Describe your situation to see which ones you may be eligible for.
- Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
- An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
- Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
- Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- Evaluation of the Performance of a Novel Prostate Biopsy System Compared With Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters
- Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
- Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
- Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
- Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
- PSMA-PET to Guide Prostatectomy
- Ultralow Dose PET Imaging for PSMA Expression
- Low-Count Quantitative SPECT for Men Treated With Radium-223
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
- PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
- Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
- Using FAPI PET/MRI to Evaluate Prostate Cancer
- Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
- An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique
- Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
- Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
- rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
- Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
- Cleveland African American Prostate Cancer Project
- Investigation of Impact of AI on Prostate Cancer Workflow
- POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
- PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
- PSMA PET for Surveillance After Focal Therapy
- Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
- MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
- ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
- Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- PET/CT Characterization of Treatment Resistance
- The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
- The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
- Imaging of Solid Tumors Using 18F-TRX
- Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
- 64Cu-GRIP B in Patients With Advanced Malignancies
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- Imaging of Solid Tumors Using FAP-2286
- The Vanguard Study: Testing a New Way to Screen for Cancer
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.